{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:16:28Z","timestamp":1754162188539,"version":"3.41.2"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Alterations in the gut microbiome composition or function are associated with risk factors for cardiometabolic diseases, including hypertension, hyperlipidemia and hyperglycemia. Based on recent evidence that also oral medications used to treat these conditions could alter the gut microbiome composition and function and, vice versa, that the gut microbiome could affect the efficacy of these treatments, we reviewed the literature on these observed interactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>While the interaction of metformin with the gut microbiome has been studied most, other drugs that target cardiometabolic risk are gaining attention and often showed associations with alterations in microbiome-related features, including alterations in specific microbial taxa or pathways, microbiome composition or microbiome-derived metabolites, while the gut microbiome was also involved in drug metabolism and drug efficacy. As for metformin, for some of them even a potential therapeutic effect via the gut microbiome is postulated. However, exact mechanisms remain to be elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There is growing interest in clarifying the interactions between the gut microbiome and drugs to treat hypertension, hyperlipidemia and hyperglycemia as well as the first pass effect of microbiome on drug efficacy. While mostly analysed in animal models, also human studies are gaining more and more traction. Improving the understanding of the gut microbiome drug interaction can provide clinical directions for therapy by optimizing drug efficacy or providing new targets for drug development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000727","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T23:56:54Z","timestamp":1608249414000},"page":"38-54","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact drugs targeting cardiometabolic risk on the gut microbiota"],"prefix":"10.1097","volume":"32","author":[{"given":"Manon","family":"Balvers","sequence":"first","affiliation":[{"name":"Department of Internal and Vascular Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam"},{"name":"Horaizon BV, Delft"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert-Jan H.","family":"van den Born","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam"},{"name":"Department of Public Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeni","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam"},{"name":"Horaizon BV, Delft"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11154-019-09533-9","article-title":"Gut microbiome and cardiometabolic risk cardiometabolic diseases gut microbiota","volume":"20","author":"Kappel","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/17446651.2020.1720511","article-title":"Gut microbiota: a promising target against cardiometabolic diseases","volume":"15","author":"Warmbrunn","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1126\/science.aad3503","article-title":"Population-level analysis of gut microbiome variation","volume":"352","author":"Falony","year":"2016","journal-title":"Science"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-018-0160-1","article-title":"Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography","volume":"24","author":"Deschasaux","year":"2018","journal-title":"Nat Med"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05184-7","article-title":"Gut microbiota associations with common diseases and prescription medications in a population-based cohort","volume":"9","author":"Jackson","year":"2018","journal-title":"Nat Commun"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of nonantibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-14177-z","article-title":"Impact of commonly used drugs on the composition and metabolic function of the gut microbiota","volume":"11","author":"Vich Vila","year":"2020","journal-title":"Nat Commun"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/bph.14965","article-title":"Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects","volume":"177","author":"Robles-Vera","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12102982","article-title":"Gut microbiota in hypertension and atherosclerosis: a review","volume":"12","author":"Verhaar","year":"2020","journal-title":"Nutrients"},{"key":"R13-20250729","first-page":"ehaa704","article-title":"Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study","author":"Verhaar","year":"2020","journal-title":"Eur Heart J"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"109040","DOI":"10.1016\/j.biopha.2019.109040","article-title":"Candesartan attenuates hypertension-associated pathophysiological alterations in the gut","volume":"116","author":"Wu","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phrs.2018.01.019","article-title":"The role of gut microbiota in the pharmacokinetics of antihypertensive drugs","volume":"130","author":"Choi","year":"2018","journal-title":"Pharmacol Res"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/HJH.0000000000000773","article-title":"Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction","volume":"34","author":"Yoo","year":"2016","journal-title":"J Hypertens"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/10717544.2018.1469687","article-title":"Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine","volume":"25","author":"Zhang","year":"2018","journal-title":"Drug Deliv"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/1354750X.2018.1432689","article-title":"Enalapril decreases rat plasma concentration of TMAO, gut bacteria-derived cardiovascular marker","volume":"23","author":"Konop","year":"2018","journal-title":"Biomarkers"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0189310","article-title":"Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite","volume":"12","author":"Jaworska","year":"2017","journal-title":"PLoS One"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"e010721","DOI":"10.1161\/JAHA.118.010721","article-title":"Sustained captopril-induced reduction in blood pressure is associated with alterations in gut\u2013brain axis in the spontaneously hypertensive rat","volume":"8","author":"Yang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/HYPERTENSIONAHA.120.14736","article-title":"Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring","volume":"75","author":"Li","year":"2020","journal-title":"Hypertension"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-016-0883-4","article-title":"High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus","volume":"16","author":"Chan","year":"2016","journal-title":"BMC Microbiol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-020-00260-w","article-title":"Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites","volume":"14","author":"Brocker","year":"2020","journal-title":"Hum Genomics"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Jie","year":"2017","journal-title":"Nat Commun"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3920\/BM2016.0231","article-title":"Beneficial effects of a probiotic blend on gastrointestinal side effects induced by leflunomide and amlodipine in a rat model","volume":"8","author":"Song","year":"2017","journal-title":"Benef Microbes"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00278","article-title":"Unraveling host\u2013gut microbiota dialogue and its impact on cholesterol levels","volume":"11","author":"Villette","year":"2020","journal-title":"Front Pharmacol"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.118.314642","article-title":"Gut microbial associations to plasma metabolites linked to cardiovascular phenotypes and risk: a cross-sectional study","volume":"124","author":"Kurilshikov","year":"2019","journal-title":"Circ Res"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2015.04.004","article-title":"Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism","volume":"132","author":"Catry","year":"2015","journal-title":"Life Sci"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.601","article-title":"Gut bacterial microbiome composition and statin intake \u2013 a systematic review","volume":"8","author":"Dias","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"R30-20250729","first-page":"1","article-title":"Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats","volume":"8","author":"Khan","year":"2018","journal-title":"Sci Rep"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40168-017-0246-x","article-title":"Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E\u2212\/\u2212 mice","volume":"5","author":"Ryan","year":"2017","journal-title":"Microbiome"},{"key":"R32-20250729","first-page":"gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","author":"Zhang","year":"2020","journal-title":"Gut"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1039\/C9FO00444K","article-title":"Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin","volume":"10","author":"Sudun","year":"2019","journal-title":"Food Funct"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2019.01947","article-title":"Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia","volume":"10","author":"Kim","year":"2019","journal-title":"Front Microbiol"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/jcm9051596","article-title":"Impact of the gut microbiota on atorvastatin mediated effects on blood lipids","volume":"9","author":"Zimmermann","year":"2020","journal-title":"J Clin Med"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fphar.2020.00522","article-title":"The effect of simvastatin on gut microbiota and lipid metabolism in hyperlipidemic rats induced by a high-fat diet","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"R37-20250729","first-page":"1","article-title":"An in vitro evaluation of the effects of different statins on the structure and function of human gut bacterial community","volume":"15","author":"Zhao","year":"2020","journal-title":"PLoS One"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41586-020-2269-x","article-title":"Statin therapy is associated with lower prevalence of gut microbiota dysbiosis","volume":"581","author":"Vieira-Silva","year":"2020","journal-title":"Nature"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62261-y","article-title":"Rosuvastatin alters the genetic composition of the human gut microbiome","volume":"10","author":"Kummen","year":"2020","journal-title":"Sci Rep"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2337\/dc17-1967","article-title":"Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans","volume":"41","author":"Fangmann","year":"2018","journal-title":"Diabetes Care"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/microorganisms8060925","article-title":"Bile acid sequestrant, sevelamer ameliorates hepatic fibrosis with reduced overload of endogenous lipopolysaccharide in experimental nonalcoholic steatohepatitis","volume":"8","author":"Tsuji","year":"2020","journal-title":"Microorganisms"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/dom.13272","article-title":"Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer","volume":"20","author":"Br\u00f8nden","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/gutjnl-2017-314553","article-title":"Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2\u2212\/\u2212mice by modulating composition, signalling and excretion of faecal bile acids","volume":"67","author":"Fuchs","year":"2018","journal-title":"Gut"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2017.02.011","article-title":"Bile acid binding resin prevents fat accumulation through intestinal microbiota in high-fat diet-induced obesity in mice","volume":"71","author":"Kusumoto","year":"2017","journal-title":"Metabolism"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4239\/wjd.v10.i3.154","article-title":"Crosstalk between gut microbiota and antidiabetic drug action","volume":"10","author":"Kyriachenko","year":"2019","journal-title":"World J Diabetes"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-pharmtox-010919-023612","article-title":"The role of the microbiome in drug response","volume":"60","author":"Pryor","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R48-20250729","first-page":"294","article-title":"Metformin: old friend, new ways of action-implication of the gut microbiome?","volume":"21","author":"Rodriguez","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ebiom.2018.11.046","article-title":"Bi-directional drug\u2013microbiome interactions of antidiabetics","volume":"39","author":"Whang","year":"2019","journal-title":"EBioMedicine"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cmet.2020.07.012","article-title":"Microbial imidazole propionate affects responses to metformin through p38\u03b3-dependent inhibitory AMPK phosphorylation","volume":"32","author":"Koh","year":"2020","journal-title":"Cell Metab"},{"key":"R53-20250729","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2019.08.003","article-title":"Host\u2013microbe\u2013drug\u2013nutrient screen identifies bacterial effectors of metformin therapy","volume":"178","author":"Pryor","year":"2019","journal-title":"Cell"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s00125-019-4848-7","article-title":"Metformin-induced changes of the gut microbiota in healthy young men: results of a nonblinded, one-armed intervention study","volume":"62","author":"Bryrup","year":"2019","journal-title":"Diabetologia"},{"key":"R55-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0204317","article-title":"Association of metformin administration with gut microbiome dysbiosis in healthy volunteers","volume":"13","author":"Elbere","year":"2018","journal-title":"PLoS One"},{"key":"R56-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life10090195","article-title":"The effects of metformin on the gut microbiota of patients with type 2 diabetes: A two-center, quasi-experimental study","volume":"10","author":"Nakajima","year":"2020","journal-title":"Life"},{"key":"R57-20250729","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/EJE-18-0826","article-title":"Metformin induces weight loss associated with gut microbiota alteration in nondiabetic obese women: a randomized double-blind clinical trial","volume":"180","author":"Ejtahed","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R58-20250729","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"R59-20250729","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2337\/dc16-1324","article-title":"Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut","volume":"40","author":"De La Cuesta-Zuluaga","year":"2017","journal-title":"Diabetes Care"},{"key":"R60-20250729","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/microorganisms8010094","article-title":"Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host","volume":"8","author":"Ch\u00e1vez-Carbajal","year":"2020","journal-title":"Microorganisms"},{"key":"R61-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mSystems.00578-19","article-title":"The gut microbial diversity of newly diagnosed diabetics but not of prediabetics is significantly different from that of healthy nondiabetics","volume":"5","author":"Gaike","year":"2020","journal-title":"mSystems"},{"key":"R62-20250729","doi-asserted-by":"crossref","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","article-title":"Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model","volume":"315","author":"Mishima","year":"2018","journal-title":"Am J Physiol Ren Physiol"},{"key":"R63-20250729","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41467-017-01682-2","article-title":"Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment","volume":"8","author":"Gu","year":"2017","journal-title":"Nat Commun"},{"key":"R64-20250729","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s00125-020-05095-7","article-title":"The glucose-lowering effects of \u03b1-glucosidase inhibitor require a bile acid signal in mice","volume":"63","author":"Qiu","year":"2020","journal-title":"Diabetologia"},{"key":"R65-20250729","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13300-017-0226-y","article-title":"Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial","volume":"8","author":"Zhang","year":"2017","journal-title":"Diabetes Ther"},{"key":"R66-20250729","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dom.12748","article-title":"Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R67-20250729","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.diabet.2019.11.005","article-title":"Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: results of a double-blind randomized trial in patients with type 2 diabetes","volume":"46","author":"van Bommel","year":"2020","journal-title":"Diabetes Metab"},{"key":"R68-20250729","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12020-019-02041-5","article-title":"Response of gut microbiota in type 2 diabetes to hypoglycemic agents","volume":"66","author":"Zhang","year":"2019","journal-title":"Endocrine"},{"key":"R69-20250729","doi-asserted-by":"crossref","first-page":"e00009","DOI":"10.1002\/edm2.9","article-title":"Gut microbiome differences between metformin- and liraglutide-treated T2DM patients","volume":"1","author":"Wang","year":"2018","journal-title":"Endocrinol Diabetes Metab"},{"key":"R70-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for human gut microbiota research?","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis Model Mech"},{"key":"R71-20250729","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota\u2013farnesoid x receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"R72-20250729","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.chom.2019.01.004","article-title":"Distinct genetic and functional traits of human intestinal prevotella copri strains are associated with different habitual diets","volume":"25","author":"De Filippis","year":"2019","journal-title":"Cell Host Microbe"},{"key":"R73-20250729","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1038\/s41467-019-12087-8","article-title":"An in vitro model maintaining taxon-specific functional activities of the gut microbiome","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"R74-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40168-020-00806-z","article-title":"RapidAIM: a culture- and metaproteomics-based rapid assay of individual microbiome responses to drugs","volume":"8","author":"Li","year":"2020","journal-title":"Microbiome"},{"key":"R75-20250729","doi-asserted-by":"crossref","first-page":"eaat9931","DOI":"10.1126\/science.aat9931","article-title":"Separating host and microbiome contributions to drug pharmacokinetics and toxicity","volume":"363","author":"Zimmermann","year":"2019","journal-title":"Science"},{"key":"R76-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/msystems.00606-19","article-title":"MICOM: metagenome-scale modeling to infer metabolic interactions in the gut microbiota","volume":"5","author":"Diener","year":"2020","journal-title":"mSystems"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:10:22Z","timestamp":1753827022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000727","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"type":"print","value":"0957-9672"},{"type":"electronic","value":"1473-6535"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}